Figure 2 | Scientific Reports

Figure 2

From: Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA

Figure 2

Cumulative incidence of graft-versus-host disease (GVHD). (A) Cumulative incidence of acute GVHD at day + 100 in MSD-PTCy group compared to MSD-control group. (B) Cumulative incidence of chronic GVHD at 1 year in MSD-PTCy group compared to MSD-control group. (C) Cumulative incidence of acute GVHD at day + 100 in haplo-HSCT group compared to haplo-control group. (D) Cumulative incidence of chronic GVHD at 1 year in haplo-HSCT group compared to haplo-control group.

Back to article page